News

News

Company NewsIndustry News

Nanjing Kati Medicine and Nanjing Children's Hospital held a GD2-CART cell therapy clinical research conference on childhood neuroblastoma

Date:2020.11.30   Views:457

Share:

Nanjing Kati Medicine and Nanjing Children's Hospital held a

 GD2-CART cell therapy clinical research conference on childhood neuroblastoma


       On November 19, the GD2-CART cell therapy clinical research on childhood neuroblastoma was held at the Children’s Hospital of Nanjing Medical University (Nanjing Children’s Hospital). The convening of this conference marked the GD2-CART cell therapy for childhood neuroblastoma. The tumor project clinical research started.


       GD2-CART is a CART drug developed by Nanjing Kati Medicine that has passed the identification of GD2 and is a Class 1.1 new drug. The director of the Department of Hematology and Oncology of Nanjing Children's Hospital serves as the general PI of this project. The deputy director of the Department of Hematology and Oncology of Nanjing Children's Hospital, assistant director, and other related researchers attended the meeting.

1 Director Fang's opening speech



2 Dr. Wang Enxiu's speech


The concept of clinical research on GD2-CART cell therapy for childhood neuroblastoma was explained, and the strength of the Katy team and the technical characteristics of Katy were introduced.


3 CTO Dr. Wang Chen reports on the results of preclinical research




4 Quan Guangkai, manager of Katti Medical, did GD2-CART
  Introduction of clinical trial protocol for childhood neuroblastoma


5 The two parties had a lively discussion on technical issues

       The experts had a lively discussion on patient screening, trial protocol and other issues and finally reached a consensus. At the end of the meeting, Director Fang Yongjun made a summary. He said: The content of this meeting is substantial, detailed explanations are in place, and issues are fully discussed. I believe that with the joint cooperation of all parties, this experiment will be completed scientifically and rigorously. Dr. Wang Enxiu, the founder of Katy Medicine, said that the treatment of solid tumors is a very complicated process. We must be firm and persistent, guard against arrogance and rashness, and do a good job of this research in a down-to-earth manner. Finally, it will help children with theoblastoma patients. Come hope.



      High-risk neuroblastoma is a malignant disease of middle to high-type in children and adolescents. It is an embryonic tumor with a high expression of ganglioside GD2 on its surface. Therefore, GD2 has become a therapeutic target for such malignant diseases. In the past few decades, anti-GD2 therapy has made great progress in the treatment of neuroblastoma, and its safety and effectiveness have been fully verified. CART treatment for GD2 has a very promising prospect.

      The unique CAR design of Katy Medicine also brings promising benefits to the clinical benefits of GD2-CART products.


      At this kick-off meeting, Director Fang and others highly recognized the clinical trial program of GD2-CART cell therapy for childhood neuroblastoma, and also supported and encouraged the Katy team.



The meeting ended successfully, and we look forward to further cooperation and exchanges.